-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in US stocks | Cardiovascular drug company Braveheart Bio (BRVE.US) shares rose more than 75% after entering the US stock market and opening

Zhitongcaijing·08/06/2026 16:57:04
Listen to the news

The Zhitong Finance App learned that on Thursday, cardiovascular pharmaceutical company Braveheart Bio (BRVE.US) entered the US stock market. As of press release, the stock had risen more than 75% to 31.405 US dollars. The IPO price is $18. Established in 2024, Braveheart Bio is a late-clinical biopharmaceutical company focused on developing innovative treatments for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company's core drug candidate BHB-1893 (also known as HRS-1893) is an oral small-molecule cardiomyosin inhibitor that specifically inhibits myocardial myosin ATPase activity, normalizes myocardial contractile performance, reduces left ventricular hypertrophy, and improves diastolic compliance. The drug obtained an exclusive global license (excluding Greater China) from Jiangsu Hengrui Pharmaceutical in China in September 2025.